|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2020
|
|
gptkbp:approvedBy
|
gptkb:COVID-19
|
|
gptkbp:ATCCode
|
J05AB16
|
|
gptkbp:CASNumber
|
1809249-37-3
|
|
gptkbp:chemicalStructureType
|
gptkb:antiviral_drug
|
|
gptkbp:contraindication
|
hypersensitivity to remdesivir
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
gptkb:antiviral_drug
|
|
gptkbp:eliminationHalfLife
|
1 hour (parent), 25 hours (metabolite)
|
|
gptkbp:hasInChIKey
|
RWWYLEGWBNMMLJ-YSOARWBDSA-N
|
|
gptkbp:hasMolecularFormula
|
C27H35N6O8P
|
|
gptkbp:hasPatent
|
US20170071964A1
WO2017089063A1
|
|
gptkbp:hasSMILES
|
CC(C)[C@@H](NC(=O)[C@@H](COP(=O)(OCC1=CN=CN1)OCC2=O)N)C(=O)N[C@@H](C)C(=O)O
|
|
gptkbp:hasUNII
|
53J0A3T2V9
|
|
gptkbp:indication
|
treatment of COVID-19
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
RNA polymerase inhibitor
|
|
gptkbp:metabolism
|
primarily hepatic
|
|
gptkbp:molecularWeight
|
602.6 g/mol
|
|
gptkbp:name
|
gptkb:Remdesivir
|
|
gptkbp:pregnancyCategory
|
Not assigned
|
|
gptkbp:prodrugOf
|
gptkb:GS-441524
|
|
gptkbp:proteinBinding
|
88-93%
|
|
gptkbp:PubChem_CID
|
gptkb:DB12161
121304016
CHEMBL2016761
D11472
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
nausea
elevated liver enzymes
hypersensitivity
|
|
gptkbp:status
|
approved
|
|
gptkbp:storage
|
store below 30°C
|
|
gptkbp:synonym
|
gptkb:Veklury
gptkb:GS-5734
|
|
gptkbp:target
|
RNA-dependent RNA polymerase
|
|
gptkbp:bfsParent
|
gptkb:dupilumab
gptkb:Dupilumab
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB12161
|